A trial of the intravenous medication Remdesivir was conducted in adults 60 and older. Patients were randomly assigned to receive either Remdesivir or a placebo for up to 10 days. The primary outcome measured was the time to recover. Preliminary results from the 1983 patients (1007 randomly assigned to get Remdesivir and 976 to get the placebo) indicated that those who received Remdesivir had a median recovery time of 11 days as compared with 14 days in those who received the placebo. This result was not statistically significant Describe the control group